The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders

Jason G. Ho, Randall L. Caldwell, Christopher J. McDougle, Danielle K. Orsagh-Yentis, Craig A. Erickson, David J. Posey, Kimberly A. Stigler

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Objectives: Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder. Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date. Methods: Electrocardiographic data were collected from children and adolescents participating in a 14-week, prospective, open-label study (n=25) of aripiprazole for irritability in pervasive developmental disorder not otherwise specified and Asperger's disorder. A 12-lead electrocardiogram was obtained at the baseline and end point visits. The electrocardiograms were evaluated for abnormal findings, and the PR, QRS, QTc, and RR intervals were recorded. The QT interval was corrected using Bazett's, United States Food and Drug Administration (FDA) Pharmacology Division, and Fridericia's formulas. Results: Twenty-four subjects received both baseline and posttreatment electrocardiograms. The mean age was 8.6 years (range 5-17 years). The average final aripiprazole dose was 7.8mg/day (range 2.5-15mg/day). There were no significant differences noted with the PR, QRS, RR, and QTc intervals after aripiprazole therapy. Also, there was no significant correlation between the dose given and the percent change in the QTc. No post-treatment QTc exceeded 440ms. Conclusions: To our knowledge, this is the first systematic evaluation of the cardiac effects of aripiprazole in children and adolescents. The results are consistent with previously published literature in adults that aripiprazole has no significant cardiac effects and can be deemed a low risk for causing sudden death. It will be important to confirm these findings in a randomized controlled trial.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume22
Issue number4
DOIs
StatePublished - Aug 1 2012

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders'. Together they form a unique fingerprint.

  • Cite this

    Ho, J. G., Caldwell, R. L., McDougle, C. J., Orsagh-Yentis, D. K., Erickson, C. A., Posey, D. J., & Stigler, K. A. (2012). The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 22(4), 277-283. https://doi.org/10.1089/cap.2011.0129